Alector, Inc.

NASDAQ:ALEC

$2.59 USD

$0.04 (1.77%)

Volume
2.73M
Average Volume
795.98K
Market Capitalization
$253.65M
P/E Ratio
-1.58
Dividend Yield
0.00%
Price Target
$4.00
Year High
$8.90
Year Low
$2.37
Payout Ratio
$0.00
Current Ratio
$3.29

Industry, Sector & symbol

Stock Exchange NASDAQ Global Select
CEO Dr. Arnon Rosenthal Ph.D.
Industry Biotechnology
Sector Healthcare
Current Symbol ALEC
CUSIP 014442107
CIK 0001653087
Web https://www.alector.com
Phone 415 231 5660
Currency USD
Employees 241
Country US

Liquidity

Debt-to-Equity Ratio 0.06
Payout Ratio 0.00
Current Ratio 3.29
Quick Ratio 3.29
Cash Ratio 0.26

Sales & Book Value

Annual Sales $97.06M
Price / Sales 4.12
Cash Flow -2.30
Price / Cash Flow -1.14
Price / Book 2.11

Price Target and Rating

Average Stock Price Forecast $4.00
High Stock Price Forecast $4.00
Low Stock Price Forecast $4.00
Forecast Upside/Downside -35.25%
Consensus Rating Strong Sell
Rating Score(0-5) 1
Research Coverage 5 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-1.56
Trailing P/E Ratio -1.58
PEG Ratio -0.32
P/E Growth -0.32
Net Income $-130.39M
Net Margin -257.54%
Pretax Margin -254.70%
Return on Equity -108.77%
Return on Assets -30.70%

Financials Score

AltmanZ Score -2.18
Piotroski Score 1.00
Working Capital 326.84M
Total Assets 516.02M
Ebit -187.75M
Market Cap 253.65M
Total Liabilities 397.09M

Poll Results

About Alector, Inc. (NASDAQ:ALEC) Stock

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk g ... ene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

2024-11-27 10:46:20

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

2024-11-26 10:29:05

On Monday, Alector, Inc.  ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

2024-11-25 16:05:00

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002.

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

2024-11-14 16:05:00

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million.

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

2024-11-06 18:50:19

Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.

Frequently Asked Questions

What is the current Alector, Inc. (ALEC) stock price?

Alector, Inc.(NASDAQ:ALEC) stock price is $2.59 in the last trading session. During the trading session, ALEC stock reached the peak price of $8.9 while $2.37 was the lowest point it dropped to. The percentage change in ALEC stock occurred in the recent session was 1.77% while the dollar amount for the price change in ALEC stock was $0.04.

ALEC's industry and sector of operation?

The NASDAQ listed ALEC is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ALEC?

Ms. Clare Hunt M.B.A. | Chief People Officer
Ms. Norah Conway | Senior Vice President of Portfolio & Program Management
Ms. Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy
Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer
Dr. Arnon Rosenthal Ph.D. | Co-Founder, Chief Executive Officer & Director

How many employees does ALEC have?

Number of ALEC employees currently stands at 241. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, US.

Link for ALEC official website?

Official Website of ALEC is: https://www.alector.com

How do I contact ALEC?

ALEC could be contacted at phone #415 231 5660 and can also be accessed through its website. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, US.

How many shares of ALEC are traded daily?

The average number of ALEC shares traded daily for last 3 months was 795.98K.

What is the market cap of ALEC currently?

The market value of ALEC currently stands at $253.65M with its latest stock price at $2.59